{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:41:50Z","timestamp":1793724110819,"version":"4.6.1"},"reference-count":247,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Programmed cell death protein 1 (PD-1)\/programmed death-ligand 1 (PD-L1) blockade has reshaped immuno-oncology, with antibodies establishing benchmarks for survival and durability of response across multiple tumor types. Yet format-related constraints of monoclonal antibodies persist, including incomplete and heterogeneous intratumoral penetration, long half-life with limited real-time toxicity control, immune-related toxicities, and context-dependent resistance within the tumor microenvironment. This Review synthesizes the current landscape and near-term prospects of complementary or alternative modalities for PD-1\/PD-L1 pathway control. Within antibody-based approaches, we first consider clinical combinations of classical PD-1\/PD-L1 antibodies and then review bispecific antibodies that integrate blockade with co-inhibition or context-dependent co-stimulation, reduced-size antibody scaffolds with tunable pharmacokinetics and diffusion, Fc-engineered formats to modulate effector functions, and locally delivered or gene-encoded fragments that intensify intratumoral exposure. Beyond conventional antibodies, we appraise non-antibody biologics and small-molecule agents, including small molecules that promote PD-L1 dimerization to occlude the PD-1 interface, as well as decoy receptors and aptamers, and delivery-focused strategies that enable spatially constrained or vectorized pathway modulation. Across these modalities, we emphasize fit-for-context design that links target biology to the physicochemical profile of each format and route of administration, and we consolidate evidence from preclinical to late-phase settings. Building on prior reviews that have cataloged clinical outcomes of PD-1\/PD-L1 antibodies and provided in-depth overviews of individual emerging modalities, this article adopts a format-centered, cross-modality conceptual framework that connects antibody-intrinsic and microenvironmental constraints to the design and emerging clinical positioning of alternative PD-1\/PD-L1-targeting modalities, to clarify when and how intensification or format switching is most likely to be beneficial. We conclude that PD-1\/PD-L1 antibodies retain a foundational role, while additional modalities are positioned to serve as\u00a0complementary or alternative options that mitigate inherent physical and biological limitations when matched to the spatial, cellular, and pharmacological constraints of individual tumors.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1729468","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:46:01Z","timestamp":1765953961000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Beyond monoclonal antibodies: constraints and the case for alternative PD-1\/PD-L1-targeting formats"],"prefix":"10.3389","volume":"16","author":[{"given":"Natalia O.","family":"Porozova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia V.","family":"Petukhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim A.","family":"Gureev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan S.","family":"Moiseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor E.","family":"Eliseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila V.","family":"Fedorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri B.","family":"Porozov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.114052","article-title":"Peripheral blood Pd-1(+) T lymphocytes as biomarkers in liquid biopsies for solid tumors: clinical significance and prognostic applications","volume":"147","author":"Piao","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/85330","article-title":"Pd-L2 is a second ligand for Pd-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of Pd-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by Pd-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00867-9","article-title":"Insights from a 30-year journey: function, regulation and therapeutic modulation of Pd1","volume":"23","author":"Chamoto","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113364","article-title":"The effects of thymoquinone on pancreatic cancer: evidence from preclinical studies","volume":"153","author":"Butnariu","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of Pd-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of Fda-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.11.010","article-title":"Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma","volume":"144","author":"Robert","year":"2021","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111876","article-title":"Progress in Pd-1\/Pd-L1 pathway inhibitors: from biomacromolecules to small molecules","volume":"186","author":"Lin","year":"2020","journal-title":"Eur J Med Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1035276","article-title":"Current landscape and future directions of bispecific antibodies in cancer immunotherapy","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8730","article-title":"Structural basis for small molecule targeting of the programmed death ligand 1 (Pd-L1)","volume":"7","author":"Zak","year":"2016","journal-title":"Oncotarget"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.11.011","article-title":"High-affinity decoy Pd-1 mutant screened from an epitope-specific cell library","volume":"7","author":"Liu","year":"2021","journal-title":"Engineering"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.3c00551","article-title":"Aptamers targeting the Pd-1\/Pd-L1 axis: A perspective","volume":"66","author":"Bertrand","year":"2023","journal-title":"J Med Chem"},{"key":"B17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12032-025-02822-1","article-title":"Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies","volume":"42","author":"Zamani","year":"2025","journal-title":"Med Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s42003-020-0845-0","article-title":"Interaction of Shp-2 Sh2 domains with Pd-1 Itsm induces Pd-1 dimerization and Shp-2 activation","volume":"3","author":"Patsoukis","year":"2020","journal-title":"Commun Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-03-3259","article-title":"Pd-L1\/B7h-1 inhibits the effector phase of tumor rejection by T cell receptor (Tcr) transgenic Cd8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41419-024-06553-5","article-title":"Metabolic remodeling by the Pd-L1 inhibitor Bms-202 significantly inhibits cell Malignancy in human glioblastoma","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1486888","article-title":"Pd-L2 act as an independent immune checkpoint in colorectal cancer beyond Pd-L1","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.09.005","article-title":"Elevated baseline serum Pd-1 or Pd-L1 predicts poor outcome of Pd-1 inhibition therapy in metastatic melanoma","volume":"31","author":"Ugurel","year":"2020","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1308381","article-title":"Soluble Pd-L1 changes in advanced non-small cell lung cancer patients treated with Pd-1 inhibitors: an individual patient data meta-analysis","volume":"14","author":"Shimizu","year":"2023","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1400262","article-title":"Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxm057","article-title":"Pd-1 and Pd-1 ligands: from discovery to clinical application","volume":"19","author":"Okazaki","year":"2007","journal-title":"Int Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14369","article-title":"An unexpected N-terminal loop in Pd-1 dominates binding by nivolumab","volume":"8","author":"Tan","year":"2017","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712278105","article-title":"The Pd-1\/Pd-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.448126","article-title":"Structure and interactions of the human programmed cell death 1 receptor","volume":"288","author":"Cheng","year":"2013","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.102","article-title":"Structural basis of anti-Pd-L1 monoclonal antibody avelumab for tumor therapy","volume":"27","author":"Liu","year":"2017","journal-title":"Cell Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, Pd-1, and its ligand Pd-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804453105","article-title":"Crystal structure of the complex between programmed death-1 (Pd-1) and its ligand Pd-L2","volume":"105","author":"Lazar-Molnar","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of Shp2 activation by Pd-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Sci Adv"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor Cd28 is a primary target for Pd-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74276","article-title":"Molecular features underlying differential Shp1\/Shp2 binding of immune checkpoint receptors","volume":"10","author":"Xu","year":"2021","journal-title":"Elife"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1016\/j.celrep.2019.05.041","article-title":"Quantitative interactomics in primary T cells provides a rationale for concomitant Pd-1 and Btla coinhibitor blockade in cancer immunotherapy","volume":"27","author":"Celis-Gutierrez","year":"2019","journal-title":"Cell Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.77","article-title":"Structural basis for blocking Pd-1-mediated immune suppression by therapeutic antibody pembrolizumab","volume":"27","author":"Na","year":"2017","journal-title":"Cell Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/antib13030077","article-title":"Residue-specific epitope mapping of the Pd-1\/nivolumab interaction using X-ray footprinting mass spectrometry","volume":"13","author":"Kristensen","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.856961","article-title":"Physiological considerations for modeling in vivo antibody-target interactions","volume":"13","author":"Dunlap","year":"2022","journal-title":"Front Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2085535","article-title":"Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies","volume":"14","author":"Rafidi","year":"2022","journal-title":"MAbs"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/btpr.3323","article-title":"Single-stage chromatographic clarification of Chinese hamster ovary cell harvest reduces cost of protein production","volume":"39","author":"O\u2019Mara","year":"2023","journal-title":"Biotechnol Prog"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032620","article-title":"Immune checkpoint inhibitors and cardiotoxicity: A comparative meta-analysis of observational studies and randomized controlled trials","volume":"13","author":"Sharma","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq026","article-title":"Pd-1 deficiency results in the development of fatal myocarditis in Mrl mice","volume":"22","author":"Wang","year":"2010","journal-title":"Int Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with Ctla4 and Pd1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116909","article-title":"Cardiac alpha-myosin heavy chains differ in their induction of myocarditis. Identification of pathogenic epitopes","volume":"92","author":"Liao","year":"1993","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2011.08.013","article-title":"Identification of novel mimicry epitopes for cardiac myosin heavy chain-alpha that induce autoimmune myocarditis in a\/J mice","volume":"271","author":"Massilamany","year":"2011","journal-title":"Cell Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006155","article-title":"Beta(1)-adrenoreceptor autoantibodies in heart failure: physiology and therapeutic implications","volume":"13","author":"Dungen","year":"2020","journal-title":"Circ Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.035128","article-title":"Role of antitroponin antibodies and macrotroponin in the clinical interpretation of cardiac troponin","volume":"13","author":"Salaun","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.64944","article-title":"Enos-induced vascular barrier disruption in retinopathy by C-Src activation and tyrosine phosphorylation of ve-cadherin","volume":"10","author":"Ninchoji","year":"2021","journal-title":"Elife"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1567293","article-title":"Anti-endothelial cell antibodies in pathogenesis of vasculitis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.123.067189","article-title":"T cells and macrophages drive pathogenesis of immune checkpoint inhibitor myocarditis","volume":"149","author":"Cihakova","year":"2024","journal-title":"Circulation"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e25747","article-title":"Immune checkpoint inhibitor-associated cardiovascular toxicities: A review","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-025-03146-7","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management","author":"Becker","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-24-114","article-title":"Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: A narrative review","volume":"14","author":"Wang","year":"2024","journal-title":"Cardiovasc Diagn Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-024-09918-6","article-title":"Steroid-refractory myocarditis induced by immune checkpoint inhibitor responded to infliximab: report of two cases and literature review","volume":"24","author":"Tan","year":"2024","journal-title":"Cardiovasc Toxicol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.annonc.2024.08.2340","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during Ici rechallenge: the tapir study","volume":"36","author":"Petit","year":"2025","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007307","article-title":"Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer","volume":"11","author":"Drobni","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.124.016851","article-title":"Longitudinal assessment of subclinical arterial inflammation in patients receiving immune checkpoint inhibitors by sequential [(18)F]Fdg pet scans","volume":"18","author":"Bacmeister","year":"2025","journal-title":"Circ Cardiovasc Imaging"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s44161-024-00563-4","article-title":"Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors","volume":"3","author":"Barcia Duran","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30514-5","article-title":"Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (Ivy): A multicentre, multicohort, open-label, phase 1b trial","volume":"20","author":"Naing","year":"2019","journal-title":"Lancet Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.10.001","article-title":"Randomized phase 2 studies of checkpoint inhibitors alone or in combination with pegilodecakin in patients with metastatic Nsclc (Cypress 1 and cypress 2)","volume":"16","author":"Spigel","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: Asco guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7010","article-title":"Life years gained from the Fda accelerated approval program in oncology: A portfolio model","volume":"22","author":"Benedict","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.07.002","article-title":"Steroids in immune checkpoint inhibitor myocarditis","volume":"6","author":"Palaskas","year":"2024","journal-title":"JACC CardioOncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1455347","article-title":"Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: A case series and systematic review","volume":"16","author":"Man","year":"2025","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjon.2024.100598","article-title":"Relevance of surveillance manual for the early detection of immune checkpoint inhibitor-induced myocarditis: A case series","volume":"11","author":"Oyakawa","year":"2024","journal-title":"Asia Pac J Oncol Nurs"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1350585","article-title":"Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach","volume":"11","author":"Murtagh","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115186","article-title":"Optimized monitoring for immune checkpoint inhibitor induced myocarditis using high-sensitivity troponin-T","volume":"216","author":"Tomsitz","year":"2025","journal-title":"Eur J Cancer"},{"key":"B73","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0026-2862(89)90074-5","article-title":"Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection","volume":"37","author":"Baxter","year":"1989","journal-title":"Microvasc Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2022.188792","article-title":"Interstitial fluid pressure as an emerging biomarker in solid tumors","volume":"1877","author":"Salavati","year":"2022","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14983","article-title":"Barriers to antibody therapy in solid tumors, and their solutions","volume":"112","author":"Matsumura","year":"2021","journal-title":"Cancer Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-255","article-title":"The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors","volume":"10","author":"Lee","year":"2010","journal-title":"BMC Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12943-023-01744-8","article-title":"Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments","volume":"22","author":"Yuan","year":"2023","journal-title":"Mol Cancer"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1638","article-title":"Improved tumor penetration and single-cell targeting of antibody-drug conjugates increases anticancer efficacy and host survival","volume":"78","author":"Cilliers","year":"2018","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0704","article-title":"Strategies to enhance monoclonal antibody uptake and distribution in solid tumors","volume":"18","author":"Bordeau","year":"2021","journal-title":"Cancer Biol Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01287","article-title":"Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors","volume":"8","author":"Xenaki","year":"2017","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","article-title":"Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours","volume":"317","author":"Debie","year":"2020","journal-title":"J Control Release"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11757","article-title":"Interferon-gamma induced Pd-L1 expression and soluble Pd-L1 production in gastric cancer","volume":"20","author":"Imai","year":"2020","journal-title":"Oncol Lett"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405485","article-title":"Pd-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunopet","volume":"15","author":"Ibrahim","year":"2024","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202303175","article-title":"Challenges coexist with opportunities: spatial heterogeneity expression of Pd-L1 in cancer therapy","volume":"11","author":"Wang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010059","article-title":"Nivolumab plasma concentration and clearance associated with overall survival in patients with renal cell carcinoma","volume":"13","author":"Maritaz","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltaf019","article-title":"High level of anti-drug antibodies is associated with shorter survival in advanced solid cancer patients treated with immune checkpoint inhibitors","volume":"5","author":"Zhao","year":"2025","journal-title":"Immunother Adv"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1578838","article-title":"Integrating clinical trial landscapes and bibliometric analysis: unveiling the impact of Pd-1\/Pd-L1 inhibitors on renal cell carcinoma research and therapeutic trajectories summary","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115373","article-title":"Safety of accelerated infusion of nivolumab and pembrolizumab","volume":"220","author":"van Rijssen","year":"2025","journal-title":"Eur J Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"OP2500052","DOI":"10.1200\/OP-25-00052","article-title":"Subcutaneous immunotherapies in solid tumors: are we truly expanding access and efficiency","author":"Ibodeng","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.03.012","article-title":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475a-D77 trial","volume":"36","author":"Felip","year":"2025","journal-title":"Ann Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of Pd-1\/Pd-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting lag-3, tim-3, and tigit for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200239","article-title":"Overall survival and response with nivolumab and relatlimab in advanced melanoma","volume":"2","author":"Long","year":"2023","journal-title":"NEJM Evid"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to Pd-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0593","article-title":"Impaired Hla class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"7","author":"Gettinger","year":"2017","journal-title":"Cancer Discov"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1157537","article-title":"Targeting myeloid-derived suppressor cells in tumor immunotherapy: current, future and beyond","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1261749","article-title":"Tumour-associated macrophages: versatile players in the tumour microenvironment","volume":"11","author":"Ji","year":"2023","journal-title":"Front Cell Dev Biol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06696-z","article-title":"Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance","volume":"623","author":"Guo","year":"2023","journal-title":"Nature"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"B103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (Mdscs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol Cancer"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad158","article-title":"Elucidating granulocytic myeloid-derived suppressor cell heterogeneity during Staphylococcus aureus biofilm infection","volume":"115","author":"Bertrand","year":"2024","journal-title":"J Leukoc Biol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658795","article-title":"Progress in targeting tumor-associated macrophages in cancer immunotherapy","volume":"16","author":"Xia","year":"2025","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623436","article-title":"Targeting myeloid cells to improve cancer immune therapy","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41568-023-00639-6","article-title":"The dynamic role of platelets in cancer progression and their therapeutic implications","volume":"24","author":"Li","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-743187","article-title":"Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents","volume":"131","author":"Xu","year":"2018","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640578","article-title":"Platelet-mediated protection of cancer cells from immune surveillance - possible implications for cancer immunotherapy","volume":"12","author":"Schmied","year":"2021","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.09.009","article-title":"Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis","volume":"20","author":"Labelle","year":"2011","journal-title":"Cancer Cell"},{"key":"B111","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-018-0669-2","article-title":"Role of platelets and platelet receptors in cancer metastasis","volume":"11","author":"Schlesinger","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101984","article-title":"Selective apoptosis of tumor-associated platelets boosts the anti-metastatic potency of Pd-1 blockade therapy","volume":"6","author":"Wu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1038\/s41467-021-27303-7","article-title":"Platelet Pd-L1 reflects collective intratumoral Pd-L1 expression and predicts immunotherapy response in non-small cell lung cancer","volume":"12","author":"Hinterleitner","year":"2021","journal-title":"Nat Commun"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20250378","article-title":"Microbiota-centered interventions to boost immune checkpoint blockade therapies","volume":"222","author":"Almonte","year":"2025","journal-title":"J Exp Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35249","article-title":"Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I\/III impower 133 trial","volume":"156","author":"Takada","year":"2025","journal-title":"Int J Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1080\/14737140.2025.2529290","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and hepatitis B: multicentre experience in a low-middle-income country","volume":"25","author":"Ba\u015f","year":"2025","journal-title":"Expert Rev Anticancer Ther"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"Aga clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"key":"B118","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40249-023-01128-6","article-title":"Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"12","author":"Xia","year":"2023","journal-title":"Infect Dis Poverty"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100851","article-title":"Late Immune-Related Adverse Events after at Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association with Survival in Patients with Advanced Nsclc","volume":"6","author":"Elghawy","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.2668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1524945","article-title":"Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis","volume":"16","author":"Lallas","year":"2025","journal-title":"Front Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2455","article-title":"Fc-silent anti-tigit antibodies potentiate antitumor immunity without depleting regulatory T cells","volume":"84","author":"Piovesan","year":"2024","journal-title":"Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335375","article-title":"The dual role of Igg4 in immunity: bridging pathophysiology and therapeutic applications","volume":"74","author":"Piseddu","year":"2025","journal-title":"Gut"},{"key":"B124","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1038\/s41467-025-60757-7","article-title":"Dual tigit and Pd-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-Pd-1 therapies: the phase 2 liverti trial","volume":"16","author":"Hsiehchen","year":"2025","journal-title":"Nat Commun"},{"key":"B125","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1038\/s41467-025-59341-w","article-title":"Mature tertiary lymphoid structures evoke intra-tumoral T and B cell responses via progenitor exhausted Cd4(+) T cells in head and neck cancer","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5356","article-title":"Deep learning model for predicting immunotherapy response in advanced non-small cell lung cancer","volume":"11","author":"Rakaee","year":"2025","journal-title":"JAMA Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17121912","article-title":"Spatial transcriptomics in lung cancer and pulmonary diseases: A comprehensive review","volume":"17","author":"Kang","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3531","DOI":"10.1038\/s41467-025-58512-z","article-title":"Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors","volume":"16","author":"Kao","year":"2025","journal-title":"Nat Commun"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaf008","article-title":"Immune-related adverse events in older adults receiving immune checkpoint inhibitors: A comprehensive analysis of the food and drug administration adverse event reporting system","volume":"54","author":"Esen","year":"2025","journal-title":"Age Ageing"},{"key":"B130","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12885-025-14108-w","article-title":"Effect and safety of immunotherapy among elder patients (Age >\/= 65) with recurrent or metastatic nasopharyngeal carcinoma","volume":"25","author":"Xie","year":"2025","journal-title":"BMC Cancer"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced Egfr-mutated non-small-cell lung cancer who progressed on Egfr tyrosine-kinase inhibitors: A systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12876-025-03754-w","article-title":"Efficacy and safety of pembrolizumab in advanced gastric and gastroesophageal junction cancer: A systematic review and meta-analysis","volume":"25","author":"Ji","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-024-04697-x","article-title":"Pharmacokinetics and clinical outcomes of low-dose nivolumab relative to conventional dose in patients with advanced cancer","volume":"94","author":"Gandhi","year":"2024","journal-title":"Cancer Chemother Pharmacol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1039\/d3md00655g","article-title":"Progress in small-molecule inhibitors targeting Pd-L1","volume":"15","author":"Xu","year":"2024","journal-title":"RSC Med Chem"},{"key":"B135","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade8520","article-title":"Jak inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma","volume":"384","author":"Zak","year":"2024","journal-title":"Science"},{"key":"B137","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2a receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.08.004","article-title":"Fcgammars modulate the anti-tumor activity of antibodies targeting the Pd-1\/Pd-L1 axis","volume":"28","author":"Dahan","year":"2015","journal-title":"Cancer Cell"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1833857","article-title":"Tislelizumab: an investigational anti-Pd-1 antibody for the treatment of advanced non-small cell lung cancer (Nsclc)","volume":"29","author":"Liu","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924542","article-title":"Penpulimab, an Fc-engineered Igg1 anti-Pd-1 Antibody, with Improved Efficacy and Low incidence of immune-related adverse events","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003735","article-title":"Fc-null anti-Pd-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments","volume":"10","author":"Moreno-Vicente","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009034","article-title":"Fc-Fc interactions and immune inhibitory effects of Igg4: implications for anti-Pd-1 immunotherapies","volume":"12","author":"Zhang","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1177\/10732748221111296","article-title":"Tislelizumab: A modified anti-tumor programmed death receptor 1 antibody","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Control"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","article-title":"Cadonilimab, a tetravalent Pd-1\/Ctla-4 bispecific antibody with trans-binding and enhanced target binding avidity","volume":"15","author":"Pang","year":"2023","journal-title":"MAbs"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05192-0","article-title":"Pd-1-Cis Il-2r agonism yields better effectors from stem-like Cd8(+) T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002447","article-title":"Cx-072 (Pacmilimab), a probody ((R)) Pd-L1 inhibitor, in advanced or recurrent solid tumors (Proclaim-cx-072): an open-label dose-finding and first-in-human study","volume":"9","author":"Naing","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1345","article-title":"Preclinical characterization and phase I trial results of a bispecific antibody targeting Pd-L1 and 4-1bb (Gen1046) in patients with advanced refractory solid tumors","volume":"12","author":"Muik","year":"2022","journal-title":"Cancer Discov"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011377","article-title":"Acasunlimab, an Fc-inert Pd-L1x4-1bb bispecific antibody, combined with Pd-1 blockade potentiates antitumor immunity via complementary immune modulatory effects","volume":"13","author":"Capello","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02593-0","article-title":"The Pd-1- and Lag-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: A phase 1 trial","volume":"29","author":"Luke","year":"2023","journal-title":"Nat Med"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from relativity-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J Clin Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.282915","article-title":"Immune checkpoint molecule Dnam-1\/Cd112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia","volume":"109","author":"Kaito","year":"2024","journal-title":"Haematologica"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1568664","article-title":"Tiragolumab and tigit: pioneering the next era of cancer immunotherapy","volume":"16","author":"Ghasemi","year":"2025","journal-title":"Front Pharmacol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02135-4","article-title":"Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (Compassion-16): A randomised, double-blind, placebo-controlled phase 3 trial in China","volume":"404","author":"Wu","year":"2024","journal-title":"Lancet"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03450-4","article-title":"First-line cadonilimab plus chemotherapy in Her2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A randomized, double-blind, phase 3 trial","volume":"31","author":"Shen","year":"2025","journal-title":"Nat Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00411-4","article-title":"Safety and antitumour activity of cadonilimab, an anti-Pd-1\/Ctla-4 bispecific antibody, for patients with advanced solid tumours (Compassion-03): A multicentre, open-label, phase 1b\/2 trial","volume":"24","author":"Gao","year":"2023","journal-title":"Lancet Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1562875","article-title":"Cadonilimab plus chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer: A cost-effectiveness analysis","volume":"16","author":"Xiang","year":"2025","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101470","article-title":"Kn046, a bispecific antibody against Pd-L1 and Ctla-4, plus chemotherapy as first-line treatment for metastatic Nsclc: A multicenter phase 2 trial","volume":"5","author":"Zhao","year":"2024","journal-title":"Cell Rep Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/s41467-024-45160-y","article-title":"The anti-Pd-L1\/Ctla-4 bispecific antibody Kn046 in combination with Nab-paclitaxel in first-line treatment of metastatic triple-negative breast cancer: A multicenter phase II trial","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2668","article-title":"Gnc-038, a tetra-specific antibody, in patients with R\/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-5681","article-title":"Abstract 5681: tetra-specific antibody Gnc-038: guidance and navigation control (Gnc) molecule development for treatment of Cd19+ Malignancies","volume":"83","author":"Khalili","year":"2023","journal-title":"Cancer Res"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adr3718","article-title":"Pd-1-targeted Cis-delivery of an Il-2 variant induces a multifaceted antitumoral T cell response in human lung cancer","volume":"17","author":"Fusi","year":"2025","journal-title":"Sci Transl Med"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.03.016","article-title":"Single-domain antibodies as therapeutics for solid tumor treatment","volume":"14","author":"Wang","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2197360","article-title":"Beyond checkpoint inhibition: Pd-1 Cis-targeting of an Il-2rbetagamma-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition","volume":"12","author":"Codarri Deak","year":"2023","journal-title":"Oncoimmunology"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02722-3","article-title":"Ivonescimab versus pembrolizumab for Pd-L1-positive non-small cell lung cancer (Harmoni-2): A randomised, double-blind, phase 3 study in China","volume":"405","author":"Xiong","year":"2025","journal-title":"Lancet"},{"key":"B165","unstructured":"Summit therapeutics hits possible snag on lung cancer drug approval: STAT news\n          \n          \n            \n              Silverman\n              E\n            \n          \n          \n          2025"},{"key":"B166","unstructured":"Ivonescimab monotherapy approved by Nmpa in China for front-line Pd-L1 positive advanced Nsclc: Summit therapeutics\n          \n          \n          \n          2025"},{"key":"B167","unstructured":"New summit data clouds approval pathway in lung cancer: BioPharma dive\n          \n          \n            \n              Gardner\n              J\n            \n          \n          \n          2025"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241814189","article-title":"Anti-tumor immunogenicity of the oncolytic virus Cf33-Hnis-antipdl1 against ex vivo peritoneal cells from gastric cancer patients","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2025.13607","article-title":"Direct effects of the small molecule Pd\u2212L1 inhibitor Bms\u2212202 on A375 melanoma cells: anti\u2212Tumor activity accompanied by increased mitochondrial function","volume":"32","author":"Zhang","year":"2025","journal-title":"Mol Med Rep"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2520","article-title":"A phase 1\/2a study of T3011, an oncolytic hsv expressing Il-12 and Pd-1 antibody, administered via intratumoral (It) injection as monotherapy in advanced solid tumors","volume":"41","author":"Ji","year":"2023","journal-title":"J Clin Oncol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14581","article-title":"Intravenous infusion (Iv) or intracavitary perfusion (Ip) of T3011, an oncolytic hsv expressing il-12 and pd-1 antibody: analyses of two phase 1 studies","volume":"42","author":"Niu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8120562","article-title":"Long-term systemic expression of a novel Pd-1 blocking nanobody from an aav vector provides antitumor activity without toxicity","volume":"8","author":"Silva-Pilipich","year":"2020","journal-title":"Biomedicines"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01095-1","article-title":"Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair\/microsatellite instability high solid tumors","volume":"14","author":"Li","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01671-w","article-title":"Envafolimab: first approval","volume":"82","author":"Markham","year":"2022","journal-title":"Drugs"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1136\/egastro-2024-100106","article-title":"Immunotherapy against colorectal cancer via delivery of anti-Pd-L1 nanobody Mrna","volume":"3","author":"Chu","year":"2025","journal-title":"eGastroenterology"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102413","article-title":"Local delivery of Il-15 and anti-Pd-L1 nanobody by in vitro-transcribed circilnb elicits superior antitumor immunity in cold tumors","volume":"6","author":"Niu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.557","article-title":"Half-life extension of single-domain antibody-drug conjugates by albumin binding moiety enhances antitumor efficacy","volume":"5","author":"Li","year":"2024","journal-title":"MedComm (2020)"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering10020122","article-title":"Bioengineering of antibody fragments: challenges and opportunities","volume":"10","author":"Pirkalkhoran","year":"2023","journal-title":"Bioengineering (Basel)"},{"key":"B179","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: A comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020371","article-title":"Promising diagnostic and therapeutic approaches based on Vhhs for cancer management","volume":"16","author":"Cong","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B181","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/celldisc.2017.4","article-title":"Structural basis of a novel Pd-L1 nanobody for immune checkpoint blockade","volume":"3","author":"Zhang","year":"2017","journal-title":"Cell Discov"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1002\/pro.5176","article-title":"On the humanization of Vhhs: prospective case studies, experimental and computational characterization of structural determinants for functionality","volume":"33","author":"Fernandez-Quintero","year":"2024","journal-title":"Protein Sci"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2516676","article-title":"Developing drug-like single-domain antibodies (Vhh) from in vitro libraries","volume":"17","author":"Erasmus","year":"2025","journal-title":"MAbs"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae102","article-title":"Model-informed drug development of envafolimab, a subcutaneously injectable Pd-L1 antibody, in patients with advanced solid tumors","volume":"29","author":"Cui","year":"2024","journal-title":"Oncologist"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.2595","article-title":"Monotherapy of envafolimab in patients with high tumor mutational burden advanced solid tumors: results from a phase II clinical trial","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13817","article-title":"First-in-human phase I study of envafolimab, a novel subcutaneous single-domain anti-Pd-L1 antibody, in patients with advanced solid tumors","volume":"26","author":"Papadopoulos","year":"2021","journal-title":"Oncologist"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01287-7","article-title":"Phase I study of envafolimab (Kn035), a novel subcutaneous single-domain anti-Pd-L1 monoclonal antibody, in Japanese patients with advanced solid tumors","volume":"40","author":"Shimizu","year":"2022","journal-title":"Invest New Drugs"},{"key":"B189","article-title":"Envafolimab (Kn035) in soft tissue sarcoma (Envasarc): clinicaltrials.Gov record. ClinicalTrials.gov","author":"Pharmaceuticals","year":"2024"},{"key":"B190","article-title":"Envafolimab (Kn035) in non\u2013small-cell lung cancer (Nsclc): clinicaltrials.Gov record (Phase 3). ClinicalTrials.gov","author":"Inc.","year":"2025"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.13310","article-title":"Population pharmacokinetics and exposure-response of subcutaneous atezolizumab in patients with non-small cell lung cancer","volume":"14","author":"Chan","year":"2025","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117141","article-title":"Small molecule inhibitors targeting Pd-L1, Ctla4, Vista, Tim-3, and Lag3 for cancer immunotherapy (2020-2024)","volume":"283","author":"Cheng","year":"2025","journal-title":"Eur J Med Chem"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2045276","article-title":"Small molecule inhibitors of programmed cell death ligand 1 (Pd-L1): A patent review (2019-2021)","volume":"32","author":"Deng","year":"2022","journal-title":"Expert Opin Ther Pat"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115149","article-title":"Small molecule inhibitors of intestinal epithelial anion exchanger Slc26a3 (Dra) with a luminal, extracellular site of action","volume":"249","author":"Cil","year":"2023","journal-title":"Eur J Medicinal Chem"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20050","article-title":"Small-molecule inhibitors of Pd-1\/Pd-L1 immune checkpoint alleviate the Pd-L1-induced exhaustion of T-cells","volume":"8","author":"Skalniak","year":"2017","journal-title":"Oncotarget"},{"key":"B196","doi-asserted-by":"publisher","first-page":"12392","DOI":"10.1038\/s41598-019-48826-6","article-title":"Comprehensive in vitro characterization of Pd-L1 small molecule inhibitors","volume":"9","author":"Ganesan","year":"2019","journal-title":"Sci Rep"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.4c00042","article-title":"Nonsymmetrically substituted 1,1\u2019-biphenyl-based small molecule inhibitors of the Pd-1\/Pd-L1 interaction","volume":"15","author":"Hec-Galazka","year":"2024","journal-title":"ACS Med Chem Lett"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114343","article-title":"Pyrazolones as inhibitors of immune checkpoint blocking the Pd-1\/Pd-L1 interaction","volume":"236","author":"Le Biannic","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115468","article-title":"Design, synthesis, and evaluation of Pd-1\/Pd-L1 small-molecule inhibitors bearing a rigid indane scaffold","volume":"256","author":"Cai","year":"2023","journal-title":"Eur J Med Chem"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29112646","article-title":"C2-symmetrical terphenyl derivatives as small molecule inhibitors of programmed cell death 1\/programmed death ligand 1 protein-protein interaction","volume":"29","author":"Klimek","year":"2024","journal-title":"Molecules"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2024.2368237","article-title":"An updated patent review on Pd-1\/Pd-L1 antagonists (2022-present)","volume":"34","author":"Uzar","year":"2024","journal-title":"Expert Opin Ther Pat"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00293","article-title":"Small-molecule inhibitors of the programmed cell death-1\/programmed death-ligand 1 (Pd-1\/Pd-L1) interaction via transiently induced protein states and dimerization of Pd-L1","volume":"60","author":"Guzik","year":"2017","journal-title":"J Med Chem"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2019.01.028","article-title":"Fragment-based screening of programmed death ligand 1 (Pd-L1)","volume":"29","author":"Perry","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00957","article-title":"Terphenyl-based small-molecule inhibitors of programmed cell death-1\/programmed death-ligand 1 protein-protein interaction","volume":"64","author":"Muszak","year":"2021","journal-title":"J Med Chem"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01682","article-title":"Discovery of small-molecule inhibitors of the Pd-1\/Pd-L1 axis that promote Pd-L1 internalization and degradation","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"B206","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B207","doi-asserted-by":"publisher","first-page":"21286","DOI":"10.1038\/s41598-022-25417-6","article-title":"Effects of small molecule-induced dimerization on the programmed death ligand 1 protein life cycle","volume":"12","author":"Chai","year":"2022","journal-title":"Sci Rep"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.1136","article-title":"Definition, incidence, and challenges for assessment of hyperprogressive disease during cancer treatment with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Park","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of incb086550: A potent and novel small-molecule Pd-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008547","article-title":"Oral Pd-L1 inhibitor Gs-4224 selectively engages Pd-L1 high cells and elicits pharmacodynamic responses in patients with advanced solid tumors","volume":"12","author":"Odegard","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0034","article-title":"Development of small molecule drugs targeting immune checkpoints","volume":"21","author":"Chen","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B212","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s42003-021-02191-1","article-title":"Pd-1 derived Ca-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy","volume":"4","author":"Sasikumar","year":"2021","journal-title":"Commun Biol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS3099","article-title":"Phase 1 trial of Ca-170, a novel oral small molecule dual inhibitor of immune checkpoints Pd-1 and vista, in patients (Pts) with advanced solid tumor or lymphomas","volume":"35","author":"Lee","year":"2017","journal-title":"J Clin Oncol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.101892","article-title":"Peptide-based inhibitors targeting the Pd-1\/Pd-L1 axis: potential immunotherapeutics for cancer","volume":"42","author":"Bojko","year":"2024","journal-title":"Transl Oncol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26020445","article-title":"Modulating protein-protein interactions by cyclic and macrocyclic peptides. Prominent strategies and examples","volume":"26","author":"Gonzalez-Muniz","year":"2021","journal-title":"Molecules"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01221","article-title":"Structure-based design of non-natural macrocyclic peptides that inhibit protein-protein interactions","volume":"60","author":"Kruger","year":"2017","journal-title":"J Med Chem"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.cclet.2018.05.028","article-title":"Discovery of macrocyclic peptide inhibitors of Pd-1\/Pd-L1 interaction","volume":"29","author":"Sun","year":"2018","journal-title":"Chin Chem Lett"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00539","article-title":"Discovery of cyclic peptide inhibitors targeting pd-L1 for cancer immunotherapy","volume":"65","author":"Fetse","year":"2022","journal-title":"J Med Chem"},{"key":"B219","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12943-023-01853-4","article-title":"Structural and biological characterization of pac65, a macrocyclic peptide that blocks Pd-L1 with equivalent potency to the Fda-approved antibodies","volume":"22","author":"Rodriguez","year":"2023","journal-title":"Mol Cancer"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1193222","article-title":"Stapled peptide protac induced significantly greater anti-Pd-L1 effects than inhibitor in human cervical cancer cells","volume":"14","author":"Shi","year":"2023","journal-title":"Front Immunol"},{"key":"B221","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s41419-022-05375-7","article-title":"High-potency Pd-1\/Pd-L1 degradation induced by peptide-protac in human cancer cells","volume":"13","author":"Dai","year":"2022","journal-title":"Cell Death Dis"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1021\/acs.joc.4c00430","article-title":"Process development of a macrocyclic peptide inhibitor of Pd-L1","volume":"89","author":"Mukherjee","year":"2024","journal-title":"J Org Chem"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-023-01889-4","article-title":"Development, characterization, and radiation dosimetry studies of (18)F-bms-986229, a (18)F-labeled Pd-L1 macrocyclic peptide pet tracer","volume":"26","author":"Kim","year":"2024","journal-title":"Mol Imaging Biol"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06680-3","article-title":"Challenges coexist with opportunities: development of a macrocyclic peptide pet radioligand for Pd-L1","volume":"51","author":"Huang","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.267186","article-title":"(18)F-Bms-986229 pet to assess programmed-death ligand 1 status in gastroesophageal cancer","volume":"65","author":"Cytryn","year":"2024","journal-title":"J Nucl Med"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01262","article-title":"Design and discovery of natural cyclopeptide skeleton based programmed death ligand 1 inhibitor as immune modulator for cancer therapy","volume":"63","author":"Sun","year":"2020","journal-title":"J Med Chem"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2021.01.022","article-title":"Converting peptides into drugs targeting intracellular protein-protein interactions","volume":"26","author":"Philippe","year":"2021","journal-title":"Drug Discov Today"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1002\/chem.201905385","article-title":"Cyclic peptides as drugs for intracellular targets: the next frontier in peptide therapeutic development","volume":"27","author":"Buckton","year":"2021","journal-title":"Chemistry"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.8b13178","article-title":"Macrocyclic peptides as drug candidates: recent progress and remaining challenges","volume":"141","author":"Vinogradov","year":"2019","journal-title":"J Am Chem Soc"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00256","article-title":"Unification of efforts to improve global access to cancer therapeutics: report from the 2022\/2023 access to essential cancer medicines stakeholder summit","volume":"10","author":"Briercheck","year":"2024","journal-title":"JCO Glob Oncol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1016730","article-title":"Hypersensitivity reactions to small molecule drugs","volume":"13","author":"Han","year":"2022","journal-title":"Front Immunol"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14010068","article-title":"Inhibitors of immune checkpoints: small molecule- and peptide-based approaches","volume":"14","author":"Fuchs","year":"2024","journal-title":"J Pers Med"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1519623112","article-title":"Engineering high-affinity Pd-1 variants for optimized immunotherapy and immuno-pet imaging","volume":"112","author":"Maute","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2019.06.004","article-title":"A pilot study of the Pd-1 targeting agent amp-224 used with low-dose cyclophosphamide and stereotactic body radiation therapy in patients with metastatic colorectal cancer","volume":"18","author":"Floudas","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbe1603028","article-title":"Biotechnological advances utilizing aptamers and peptides refining Pd-L1 targeting","volume":"16","author":"Timilsina","year":"2024","journal-title":"Front Biosci (Elite Ed)"},{"key":"B237","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s00299-025-03475-0","article-title":"An engineered Pd1-Fc fusion produced in N. Benthamiana plants efficiently blocks Pd1\/Pdl1 interaction","volume":"44","author":"Izadi","year":"2025","journal-title":"Plant Cell Rep"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129943","article-title":"Pd-L1 DNA aptamers isolated from agarose-bead selex","volume":"112","author":"Mohd Nazri","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27051482","article-title":"Novel complex of Pd-L1 aptamer and albumin enhances antitumor efficacy in vivo","volume":"27","author":"An","year":"2022","journal-title":"Molecules"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1039\/d4tb01831a","article-title":"Radiation-activated Pd-L1 aptamer-functionalized nanoradiosensitizer to potentiate antitumor immunity in combined radioimmunotherapy and photothermal therapy","volume":"12","author":"Chen","year":"2024","journal-title":"J Mater Chem B"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1039\/d0tb01668c","article-title":"Anti-Pd-L1 DNA aptamer antagonizes the interaction of Pd-1\/Pd-L1 with antitumor effect","volume":"9","author":"Gao","year":"2021","journal-title":"J Mater Chem B"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2022.06.059","article-title":"In vivo positron emission tomography imaging for Pd-L1 expression in cancer using aptamer","volume":"620","author":"Choi","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00818","article-title":"Multifunctional probe based on \u201cChemical antibody-aptamer\u201d for noninvasive detection of Pd-L1 expression in cancer","volume":"21","author":"Kong","year":"2024","journal-title":"Mol Pharm"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0482","article-title":"Neutralization of Pd-L2 is essential for overcoming immune checkpoint blockade resistance in ovarian cancer","volume":"27","author":"Miao","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.11","article-title":"Targeting the Pd-1\/Pd-L1 immune evasion axis with DNA aptamers as a novel therapeutic strategy for the treatment of disseminated cancers","volume":"4","author":"Prodeus","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"B246","doi-asserted-by":"publisher","first-page":"e397","DOI":"10.1038\/mtna.2016.102","article-title":"A novel Pd-L1-targeting antagonistic DNA aptamer with antitumor effects","volume":"5","author":"Lai","year":"2016","journal-title":"Mol Ther Nucleic Acids"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1224339","article-title":"Pd-L1 aptamer-functionalized degradable hafnium oxide nanoparticles for near infrared-ii diagnostic imaging and radiosensitization","volume":"11","author":"Wei","year":"2023","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1729468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T06:46:14Z","timestamp":1765953974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1729468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":247,"alternative-id":["10.3389\/fimmu.2025.1729468"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1729468","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"article-number":"1729468"}}